Assessing efficacy and safety of genome EDITing approaches for Sickle Cell Disease

Projektinformationen

EDITSCD

ID Finanzhilfevereinbarung: 101057659

DOI 10.3030/101057659

EK-Unterschriftsdatum 24 Mai 2022

Startdatum 1 September 2022

Enddatum 31 August 2027

Finanziert unter

• Health

Gesamtkosten € 6 532 000,00

EU-Beitrag € 6 532 000,00

Koordiniert durch

IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION
France

Leistungen

Documents, reports (2)

Data Management Plan 2

We will revise the data management plan (see paragraph 1.2.6) at month 18

Data Management Plan 1

A document describing the data management plan (see paragraph 1.2.6) will be produced and provided at month 6

Websites, patent fillings, videos etc. (1)

Project website and logo

A web page will be created in English for information of patients, families, patient organizations, the general public, health care providers, financial actors on the aims and progress of the project.

Veröffentlichungen

Peer reviewed articles (1)

Clinical genome editing to treat sickle cell disease—A brief update

Autoren: Parinaz Zarghamian; Julia Klermund; Toni Cathomen
Veröffentlicht in: Crossref, 2023, ISSN 2296-858X
Herausgeber: Frontiers in Medecine
DOI: 10.3389/fmed.2022.1065377